By USFDA
Orchid Pharma has received the Establishment Inspection Report from USFDA based on the successful inspection closure for the Post-marketing Adverse Drug Experience reporting Inspection (PADE) conducted at Orchid Tower 313, Valluvar Kottam High Road, Nungambakkam, Chennai. The facility was inspected by USFDA in the month of June 2017.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
